Literature DB >> 27908253

Assessment of Bone Quality in Osteoporosis Treatment with Bone Anabolic Agents: Really Something New?

Fabio M Ulivieri1, Renata Caudarella2, Marzia Camisasca3, Daniela M Cabrini4, Ilaria Merli4, Carmelo Messina4, Luca P Piodi5.   

Abstract

Osteoporosis is a chronic pathologic condition, particularly of the elderly, in which a reduction of bone mineral density (BMD) weakens bone, leading to the so-called fragility fractures, most often of spine and femur. The gold standard exam for the quantitative measurement of BMD is the dual X-ray photon absorptiometry (DXA), a radiological method. However, a relevant number of fragility fractures occurs in the range of normal BMD values, meaning that also qualitative aspects of bone play a role, namely bone architecture and bone geometry. Bone structure is investigated by microCT and histomorphometry, which necessitate an invasive approach with a biopsy, usually taken at the iliac crest, not the typical site of fragility fractures. New tools, trabecular bone score (TBS) and hip structural analysis (HSA), obtained during DXA, can supply informations about bone structure of spine and femur, respectively, in a not invasive way. Therapy of osteoporosis is based on two types of drugs leading to an increase of BMD: antiresorptive and anabolic treatments. The antiresorptive drugs inhibit the osteoclasts, whereas teriparatide and, in part, strontium ranelate ameliorate bone structure. The present review deals with the relation between the anabolic drugs for osteoporosis and the cited new tools which investigate bone architecture and geometry, in order to clarify if they represent a real advantage in monitoring efficacy of osteoporosis' treatment. Data from the studies show that increases of TBS and HSA values after anabolic therapy are small and very close to their least significant change at the end of the usual period of treatment. Therefore, it is questionable if TBS and HSA are really helpful in monitoring bone quality and in defining reduction of individual fragility fracture risk during osteoporosis treatment with bone anabolic agents. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.org.

Entities:  

Keywords:  DXA; HSA; TBS; anabolic Agents; anabolic therapy; antiresorptive drugs; osteoporosis.

Mesh:

Substances:

Year:  2018        PMID: 27908253     DOI: 10.2174/1573397112666161201162322

Source DB:  PubMed          Journal:  Curr Rheumatol Rev        ISSN: 1573-3971


  4 in total

1.  Research trends in trabecular bone score: A bibliometric review from 2008 to 2019.

Authors:  Malcolm Koo; Tzyy-Ling Chuang; Yuh-Feng Wang
Journal:  Tzu Chi Med J       Date:  2021-03-15

2.  Effectiveness of thiazides on serum and urinary calcium levels and bone mineral density in patients with osteoporosis: a systematic review and meta-analysis.

Authors:  Lei Cheng; Keyan Zhang; Zhenyong Zhang
Journal:  Drug Des Devel Ther       Date:  2018-11-14       Impact factor: 4.162

3.  Artificial neural network analysis of bone quality DXA parameters response to teriparatide in fractured osteoporotic patients.

Authors:  Carmelo Messina; Luca Petruccio Piodi; Enzo Grossi; Cristina Eller-Vainicher; Maria Luisa Bianchi; Sergio Ortolani; Marco Di Stefano; Luca Rinaudo; Luca Maria Sconfienza; Fabio Massimo Ulivieri
Journal:  PLoS One       Date:  2020-03-11       Impact factor: 3.240

4.  In vivo Labeling of Bone Microdamage in an Animal Model of Type 1 Diabetes Mellitus.

Authors:  Sahar Mohsin; Suneesh Kaimala; Eman Khamis Yousef AlTamimi; Saeed Tariq; Ernest Adeghate
Journal:  Sci Rep       Date:  2019-11-18       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.